Alamea Verwaltungs GmbH Buys New Position in Labcorp Holdings Inc. $LH

Alamea Verwaltungs GmbH bought a new stake in Labcorp Holdings Inc. (NYSE:LH) during the 4th quarter, Holdings Channel.com reports. The firm bought 2,689 shares of the medical research company’s stock, valued at approximately $730,000. Labcorp comprises about 0.5% of Alamea Verwaltungs GmbH’s portfolio, making the stock its 28th largest position.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC bought a new position in shares of Labcorp during the 4th quarter worth approximately $991,000. Integrated Wealth Concepts LLC boosted its holdings in shares of Labcorp by 7.9% during the 1st quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company’s stock worth $565,000 after buying an additional 177 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Labcorp by 52.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company’s stock worth $82,353,000 after buying an additional 121,304 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in shares of Labcorp during the 2nd quarter worth approximately $5,873,000. Finally, First Trust Advisors LP boosted its holdings in shares of Labcorp by 83.2% during the 2nd quarter. First Trust Advisors LP now owns 86,046 shares of the medical research company’s stock worth $22,588,000 after buying an additional 39,087 shares in the last quarter. 95.94% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Adam H. Schechter sold 5,903 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the completion of the sale, the chief executive officer directly owned 107,234 shares of the company’s stock, valued at approximately $27,291,053. This represents a 5.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn W. Kyle sold 762 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $263.89, for a total value of $201,084.18. Following the sale, the executive vice president directly owned 3,813 shares of the company’s stock, valued at approximately $1,006,212.57. This represents a 16.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.84% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on LH. Piper Sandler increased their price target on Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Robert W. Baird set a $334.00 price target on Labcorp in a report on Friday, May 1st. Evercore restated an “outperform” rating and set a $300.00 price target on shares of Labcorp in a report on Wednesday, April 8th. Morgan Stanley restated an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Finally, JPMorgan Chase & Co. increased their price target on Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $308.00.

Labcorp Price Performance

Shares of NYSE:LH opened at $265.45 on Friday. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. Labcorp Holdings Inc. has a twelve month low of $241.81 and a twelve month high of $293.72. The stock’s 50 day moving average is $262.65 and its 200-day moving average is $265.77. The firm has a market capitalization of $21.77 billion, a price-to-earnings ratio of 23.51, a PEG ratio of 1.86 and a beta of 0.90.

Labcorp (NYSE:LH) last issued its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.Labcorp’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Sell-side analysts forecast that Labcorp Holdings Inc. will post 18 EPS for the current fiscal year.

Labcorp Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 11th. Investors of record on Friday, May 29th were given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend was Friday, May 29th. Labcorp’s dividend payout ratio is presently 25.51%.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.